Autoimmune bullous disease in Kabul carries a measurable quality-of-life burden
Patients living with autoimmune bullous disease in Kabul experienced a substantial day-to-day burden, and the impact tracked closely with how severe the skin disease had become. In this cross-sectional study from Maiwand Teaching Hospital, moderate impairment was the rule rather than the exception, with mean ABQOL and TABQOL scores landing in a range that reflects clear disruption of normal life.
The cohort included 105 patients aged 16 years and older, with a mean age of 54.60 years and a slight female predominance. Pemphigus vulgaris accounted for 80.0% of diagnoses, making it the dominant clinical phenotype in the series. That distribution matters clinically because pemphigus vulgaris is often painful, persistent, and functionally invasive; erosions of the skin and mucosa are rarely cosmetic alone. They interfere with eating, speaking, sleeping, dressing, and the basic predictability people need to keep working or caring for family members.
Severity scores moved in step with patient experience
A single sentence captures the core pattern: worse skin disease meant worse lived experience.
Disease severity was measured with the ABSIS, a tool that rises as blistering and erosion burden increases. Both quality-of-life instruments used here moved in the same direction as disease severity, with significant positive correlations between ABSIS and ABQOL and between ABSIS and TABQOL. The relationship was strong for ABQOL, with r = 0.705, and still substantial for TABQOL, with r = 0.528, both with P < 0.001. In practical terms, these data show that patient-reported suffering did not drift away from the clinical severity score; it rose alongside it.
That alignment is biologically plausible. Autoimmune blistering disease does not merely injure the epidermis. It creates chronic pain, pruritus, open lesions, secondary infection risk, scarring anxiety, treatment burden, and visible disfigurement. The resulting stress can amplify perceived symptom burden and reduce adherence to prolonged therapy, especially in settings where access to specialist follow-up is inconsistent. When disease activity remains high, every layer of life becomes harder to manage.
Comorbidity and diagnosis shaped the burden more than sex or education
Comorbid illness separated one subgroup from the rest. Patients with comorbidities had significantly higher ABQOL scores, with P = 0.007, indicating poorer quality of life in the presence of additional medical problems. The finding is clinically intuitive: autoimmune blistering disease in an older population rarely arrives alone, and coexisting disease can intensify fatigue, limit mobility, complicate medication use, and increase the psychological load of chronic care.
Diagnosis also mattered. ABQOL differed significantly by disease type, with worse scores among patients with pemphigus vulgaris than among those with other autoimmune bullous conditions, with P < 0.001. No significant differences appeared by sex or educational status. Those null findings are important because they suggest that the burden was being driven more by the biology and severity of the skin disease than by demographic separation within this cohort.
The average ABQOL score was 23.85 ± 7.15, and the average TABQOL score was 21.05 ± 6.26. Because both instruments use higher scores to indicate worse quality of life, those values place the group squarely in a range of moderate impairment. They do not describe a mild nuisance; they describe a disease that is repeatedly intruding on daily function and treatment tolerance.
Why this matters in a resource-limited setting
Afghanistan adds a second layer of clinical concern. In resource-limited settings, chronic dermatologic disease can be harder to diagnose early, harder to monitor closely, and harder to treat consistently. Laboratory access, medication availability, transportation, and continuity of specialist care can all shape whether autoimmune disease settles down or continues to flare. When blistering disease remains active, the quality-of-life penalty rises in parallel.
The study was conducted at Maiwand Teaching Hospital in Kabul between December 2024 and March 2026, and it used the Persian versions of ABQOL and TABQOL alongside ABSIS scoring. The use of validated patient-reported measures strengthens the clinical relevance of the findings, because it captures what patients actually feel rather than relying only on physician inspection of lesions. In a disease where symptom burden, disfigurement, and treatment side effects may all matter at once, that perspective is essential.
The treatment implications are straightforward. Control of disease activity should not be viewed only as a laboratory or dermatologic endpoint. It is also a quality-of-life intervention. Better suppression of blister formation, earlier recognition of flares, and more deliberate attention to comorbid illness are likely to improve the lives of these patients in ways a skin exam alone cannot capture.
What the Kabul cohort adds to the global picture
The study fills an important gap because data from Afghanistan had been lacking. That absence matters in autoimmune blistering disease, where local health-system realities can change the patient experience substantially. Even within the same diagnosis, severity, support systems, and treatment access can shape outcomes in different ways from one region to another.
Ethical approval was obtained from Kabul University of Medical Sciences, and written informed consent was secured from all participants. For illiterate participants, study information and consent were explained verbally in their native language, with thumbprint documentation in the presence of an impartial witness. Those details are not peripheral. They show that the cohort was assembled with attention to ethical enrollment in a setting where literacy barriers could otherwise exclude vulnerable patients from research.
The authors found no funding source and reported no competing interests. Those disclosures do not alter the clinical signal, but they do frame the work as an investigator-driven effort to document disease burden in a population that has been underrepresented in the literature.
The main limitation is the cross-sectional design, which captures association rather than disease trajectory. It cannot tell whether tighter disease control will reliably improve ABQOL and TABQOL in this population, even though the relationship is biologically and clinically persuasive. Longitudinal follow-up in Afghan patients with autoimmune bullous disease would be needed to measure whether improvements in severity translate into sustained gains in daily function, symptom relief, and treatment tolerance.